Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT
Status:
Completed
Trial end date:
2020-10-12
Target enrollment:
Participant gender:
Summary
The study is designed as a two arm randomized Phase II, multicenter trial comparing
cyclophosphamide to anti-thymocyte globulin for Graft-versus-Host Disease (GVHD) prophylaxis
in patients with hematologic malignancies undergoing reduced intensity conditioning
hematopoietic stem cell transplantation.